| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/17/2005 | US20050037419 Compositions and methods relating to lung specific genes and proteins |
| 02/17/2005 | US20050037376 Sulfatase polypeptide for use in treatment and prevention of microbial infection, cell proliferative, neurodegenerative and cardiovascular disorders |
| 02/17/2005 | US20050037081 Novel formulation |
| 02/17/2005 | US20050037024 Matrix metalloprotease inhibitor |
| 02/17/2005 | US20050037009 Methods and reagents for protease inhibition |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050035267 Furnace mount and method of installation |
| 02/17/2005 | US20050035266 Furnace Mount and Method of Installation |
| 02/17/2005 | CA2535066A1 Macrophage activation inhibitor |
| 02/17/2005 | CA2534528A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparationand use as modulators of apoptosis |
| 02/17/2005 | CA2533182A1 Dry syrup containing loratadine |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1506969A1 Compounds with growth hormone releasing properties |
| 02/16/2005 | EP1506967A1 Dipeptidyl peptidase inhibitors |
| 02/16/2005 | EP1506962A2 Nitrogen-containing aromatic heterocycles |
| 02/16/2005 | EP1506958A1 Process for producing shogaol and intermediates for the synthesis thereof |
| 02/16/2005 | EP1506786A1 Medicinal compositions containing ghrelin |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506778A1 TGF-a EXPRESSION INHIBITORS |
| 02/16/2005 | EP1506777A1 Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient |
| 02/16/2005 | EP1506774A1 Smooth muscle peristole inhibitor |
| 02/16/2005 | EP1506755A2 Patient temperature regulation apparatus |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506405A1 Method for identification of a ligand whereby receptor residence time is measured |
| 02/16/2005 | EP1506215A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| 02/16/2005 | EP1506214A1 6-11 bicyclic ketolide derivatives |
| 02/16/2005 | EP1506205A2 Novel azacyclic ethynyl derivatives |
| 02/16/2005 | EP1506204A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 02/16/2005 | EP1506202A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof |
| 02/16/2005 | EP1506200A2 Novel diazabicyclic biaryl derivatives |
| 02/16/2005 | EP1506195A2 Non-nucleoside reverse transcriptase inhibitors |
| 02/16/2005 | EP1506192A1 Substituted pyrroline kinase inhibitors |
| 02/16/2005 | EP1506191A1 Benzoxazine and benzoxazinone substituted triazoles |
| 02/16/2005 | EP1506188A1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/16/2005 | EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 02/16/2005 | EP1506185A1 Novel compounds and their use |
| 02/16/2005 | EP1506181A1 Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| 02/16/2005 | EP1506180A1 Thiazolidine-4-one derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/16/2005 | EP1506179A1 Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
| 02/16/2005 | EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/16/2005 | EP1506166A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| 02/16/2005 | EP1506040A2 Selective inos inhibitors for the treatment of respiratory diseases and conditions |
| 02/16/2005 | EP1506015A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506009A2 Glucan-based vaccines |
| 02/16/2005 | EP1506000A1 Heterocyclicsulfonamide hepatitis c virus inhibitors |
| 02/16/2005 | EP1505993A1 Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
| 02/16/2005 | EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| 02/16/2005 | EP1505977A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 02/16/2005 | EP1505976A1 Synergistic combination of an opioid analgesic and a nsaid |
| 02/16/2005 | EP1505974A2 Use of compounds that are effective as selective opiate receptor modulators |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505971A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 02/16/2005 | EP1505968A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| 02/16/2005 | EP1505965A1 Use of valsartan ot its metabolite to inhibit platelet aggregation |
| 02/16/2005 | EP1505963A1 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1505962A2 Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s) |
| 02/16/2005 | EP1505959A1 Use of edg receptor binding agents in cancer |
| 02/16/2005 | EP1425258A4 Hydroxyeicosenoic acid analogs |
| 02/16/2005 | EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 02/16/2005 | EP1395553B1 Pyrrolidine derivatives as factor xa inhibitors |
| 02/16/2005 | EP1377584B1 Novel cyclohexenyl phenyl diazepines as vasopressin and oxytocin receptor modulators |
| 02/16/2005 | EP1339675B1 Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1294741B1 Dipeptide inhibitors for the blood-clotting factor xa |
| 02/16/2005 | EP1281709B1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/16/2005 | EP1268463B1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1244617B1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 02/16/2005 | EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 02/16/2005 | EP0986540B1 The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers |
| 02/16/2005 | EP0957926B1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/16/2005 | EP0944610B1 Asymmetric synthesis of benzoxazinones |
| 02/16/2005 | EP0833643B1 Anhydrous alendronate monosodium salt formulations and their use for the treatment of bone diseases |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582330A In-vitro micro-organs and uses realated thereto |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582296A Template-fixed peptidomimeticsas inhibitors of serine proteases |
| 02/16/2005 | CN1582295A Novel epidermal growth factor protein and gene, and methods of use therefor |
| 02/16/2005 | CN1582288A Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 |
| 02/16/2005 | CN1582287A Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors |
| 02/16/2005 | CN1582286A Novel 4-2-furoylaminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same |
| 02/16/2005 | CN1582284A Aminopyrimidines and pyridines |
| 02/16/2005 | CN1582281A Mch受体拮抗剂 Mch receptor antagonist |
| 02/16/2005 | CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| 02/16/2005 | CN1582279A Peroxisome proliferator activated receptor agonists |
| 02/16/2005 | CN1582278A Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same |
| 02/16/2005 | CN1582277A Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 02/16/2005 | CN1582276A Phenylalanine enamide derivatives |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582269A Hydroxyeicosenoic acid analogs |
| 02/16/2005 | CN1582169A Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| 02/16/2005 | CN1582168A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/16/2005 | CN1582167A Cytokine-inducing material and cytokine-inducing tool |
| 02/16/2005 | CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 02/16/2005 | CN1582165A Antibodies to CD40 |